Bosserhoff A K, Lederer M, Kaufmann M, Hein R, Stolz W, Apfel R, Bogdahn U, Buettner R
Department of Pathology, University of Regensburg Medical School, Germany.
Anticancer Res. 1999 Jul-Aug;19(4A):2691-3.
MIA was isolated previously as a small soluble protein secreted from malignant melanoma cell lines in vitro. Highly restricted expression patterns in melanocytic tumors were identified in vivo. We therefore quantitated serum levels of MIA protein by means of a non-radioactive ELISA and investigated whether MIA provides clinically relevant parameters in patients with malignant melanomas. Here we report enhanced MIA serum levels in 13% and 23% of patients with stage I and II disease, respectively, and in 100% with stage III or IV disease. Response to therapy in stage IV disease correlated with changes in MIA serum levels and surgical removal of metastases led to normalization of serum values. Repeated measuring of sera from 350 patients with a history of stage I or II melanoma during follow-up, we detected 32 patients developing positive MIA values. At the time of serum analysis 15 of them had developed metastases and one presented with metastatic disease 6 months later. In conclusion, MIA represents a novel serum marker for systemic malignant melanoma revealing the highest sensitivity and specificity among currently available markers.
黑色素瘤抑制活性（MIA）先前是作为一种在体外从恶性黑色素瘤细胞系分泌的小可溶性蛋白分离出来的。在体内已确定其在黑素细胞肿瘤中的高度受限表达模式。因此，我们通过非放射性酶联免疫吸附测定法（ELISA）对MIA蛋白的血清水平进行了定量，并研究了MIA是否能为恶性黑色素瘤患者提供临床相关参数。在此我们报告，I期和II期疾病患者中分别有13%和23%的患者血清MIA水平升高，而III期或IV期疾病患者中100%的患者血清MIA水平升高。IV期疾病的治疗反应与MIA血清水平的变化相关，转移灶的手术切除导致血清值恢复正常。在随访期间对350例有I期或II期黑色素瘤病史的患者的血清进行重复检测，我们检测到32例患者的MIA值呈阳性。在进行血清分析时，其中15例已发生转移，1例在6个月后出现转移性疾病。总之，MIA是一种用于系统性恶性黑色素瘤的新型血清标志物，在目前可用的标志物中显示出最高的敏感性和特异性。
